Table 2.
Summary of Curcumin Nanoformulation Pharmacokinetics
| Nanoparticles | DLS Size (nm) | Zeta potential (mV) | Loading capacity (%) | Dose (mg/kg) | Species | Plasma volume# (mL/kg) | Tmax (min) | Cmax (μg/mL) | % of dose in plasma at Tmax## | Ref |
|---|---|---|---|---|---|---|---|---|---|---|
| PEG-PCL | 27.3 | N.A. | 12.95 | 100 | rat | 31.2 | 5 | 430 | 13.4 | 32 |
| PLGA | 163 | −12.5 | 4.69 | 25 | rat | 31.2 | 15 | 16 | 2.0 | 16 |
| TPGS* | 210 | −14.8 | N.A. | 15 | rabbit | 44 | 5 | 25.5 | 7.5 | 35 |
| PLGA/PVA** | 317 | −24.2 | 1.54 | 2.5 | rat | 31.2 | 5 | 0.83 | 1.0 | 33 |
| Polybutylcyanoacrylate | 152 | 0 | 21.1 | 5 | mouse | 50 | 5 | 1.28 | 1.3 | 36 |
| PLGA-PEG-PLGA | 26.3 | −0.71 | 6.40 | 10 | mouse | 50 | 5 | 2.17 | 1.1 | 34 |
| GMO***/pluronic F-127 | 192 | −32 | 0.67 | 30 | mouse | 50 | 60 | 25 | 4.2 | 30 |
| NIPAAM/VP/AA | 92.4 | −20.1 | 0.93 | 10 | rat | 31.2 | 15 | 25.5 | 8.0 | This study |
*
TPGS: D-α-tocopheryl polyethylene glycol-succinate
**
PVA: poly (vinyl alcohol)
***
GMO: glycerol monooleate
#
Plasma volumes of mouse, rat, and rabbit were collected from literature24.
##
% of dose in plasma at Tmax = [Cmax (mg/mL) × Plasma Volume (mL/kg)] ÷ Dose (mg/kg) × 100%